false 12-31 2025 Q1 0001051514 0.1 0.1 P1Y P3Y P1Y P1Y P1Y P1Y P1Y P1Y 0001051514 2025-01-01 2025-03-31 0001051514 2025-05-12 0001051514 2025-03-31 0001051514 2024-12-31 0001051514 2024-01-01 2024-03-31 0001051514 us-gaap:CommonStockMember 2024-12-31 0001051514 2023-12-31 0001051514 us-gaap:RetainedEarningsMember 2024-12-31 0001051514 us-gaap:RetainedEarningsMember 2023-12-31 0001051514 us-gaap:CommonStockMember 2023-12-31 0001051514 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001051514 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001051514 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001051514 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001051514 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001051514 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001051514 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001051514 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001051514 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001051514 us-gaap:CommonStockMember 2025-03-31 0001051514 us-gaap:CommonStockMember 2024-03-31 0001051514 us-gaap:RetainedEarningsMember 2025-03-31 0001051514 us-gaap:RetainedEarningsMember 2024-03-31 0001051514 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001051514 2024-03-31 0001051514 us-gaap:NonUsMember sskn:XTRACMember 2025-01-01 2025-03-31 0001051514 sskn:XTRACMember country:US 2025-01-01 2025-03-31 0001051514 us-gaap:CommonStockMember 2024-04-26 2024-04-26 0001051514 srt:MaximumMember 2025-01-01 2025-03-31 0001051514 srt:MinimumMember 2025-01-01 2025-03-31 0001051514 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001051514 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001051514 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001051514 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001051514 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001051514 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001051514 sskn:AtTheMarketOfferingMember 2025-01-01 2025-03-31 0001051514 country:KR 2025-03-31 0001051514 2028-01-01 sskn:DermatologyRecurringProceduresMember 2025-03-31 0001051514 2026-01-01 sskn:DermatologyRecurringProceduresMember 2025-03-31 0001051514 2025-04-01 sskn:DermatologyRecurringProceduresMember 2025-03-31 0001051514 2027-01-01 sskn:DermatologyRecurringProceduresMember 2025-03-31 0001051514 sskn:DermatologyRecurringProceduresMember 2025-03-31 0001051514 2025-04-01 2025-03-31 0001051514 srt:MinimumMember 2025-04-01 2025-03-31 0001051514 2025-04-01 srt:MaximumMember 2025-03-31 0001051514 us-gaap:FurnitureAndFixturesMember 2025-03-31 0001051514 us-gaap:AssetUnderConstructionMember 2025-03-31 0001051514 us-gaap:AssetUnderConstructionMember 2024-12-31 0001051514 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001051514 sskn:LasersPlacedInServiceMember 2025-03-31 0001051514 us-gaap:OfficeEquipmentMember 2024-12-31 0001051514 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001051514 us-gaap:OfficeEquipmentMember 2025-03-31 0001051514 sskn:LasersPlacedInServiceMember 2024-12-31 0001051514 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001051514 us-gaap:DevelopedTechnologyRightsMember 2025-03-31 0001051514 us-gaap:TradeNamesMember 2024-12-31 0001051514 sskn:ProductTechnologyMember 2025-03-31 0001051514 sskn:ProductTechnologyMember 2024-12-31 0001051514 us-gaap:TradeNamesMember 2025-03-31 0001051514 us-gaap:CustomerListsMember 2025-03-31 0001051514 us-gaap:CustomerRelationshipsMember 2025-03-31 0001051514 us-gaap:CustomerListsMember 2024-12-31 0001051514 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0001051514 us-gaap:CustomerRelationshipsMember 2024-12-31 0001051514 sskn:SeniorTermFacilityMember sskn:MidCapFinancialTrustMember 2025-03-31 0001051514 sskn:SeniorTermFacilityAmendmentMember sskn:MidCapFinancialTrustMember 2025-03-31 0001051514 sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityAmendmentMember 2025-01-01 2025-03-31 0001051514 sskn:SeniorTermFacilityAmendmentMember sskn:MidCapFinancialTrustMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2025-01-01 2025-03-31 0001051514 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-09-06 2022-09-06 0001051514 sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityMember sskn:LondonInterbankOfferedRateMember 2025-01-01 2025-03-31 0001051514 sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityMember 2025-01-01 2025-03-31 0001051514 sskn:SeniorTermFacilityCreditFacility1Member sskn:MidCapFinancialTrustMember 2025-01-01 2025-03-31 0001051514 sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityCreditFacility2Member 2025-01-01 2025-03-31 0001051514 sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityCreditFacility3Member 2025-03-31 0001051514 sskn:MidCapFinancialTrustMember srt:MinimumMember sskn:SeniorTermFacilityMember 2025-01-01 2025-03-31 0001051514 sskn:SeniorTermFacilityCreditFacility3Member sskn:MidCapFinancialTrustMember 2025-01-01 2025-03-31 0001051514 sskn:SeniorTermFacilityMember sskn:MidCapFinancialTrustMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001051514 us-gaap:WarrantMember sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityMember 2025-01-01 2025-03-31 0001051514 us-gaap:WarrantMember sskn:SeniorTermFacilityMember sskn:MidCapFinancialTrustMember 2025-03-31 0001051514 us-gaap:CommonStockMember sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityMember 2025-03-31 0001051514 sskn:MidCapFinancialTrustMember sskn:SeniorTermFacilityThirdAmendmentMember 2025-03-31 0001051514 sskn:SeniorTermFacilityFourthAmendmentMember sskn:MidCapFinancialTrustMember 2025-03-31 0001051514 sskn:SeniorTermFacilityMember sskn:MidCapFinancialTrustMember 2024-01-01 2024-03-31 0001051514 sskn:StockIncentivePlan2016Member 2025-03-31 0001051514 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001051514 us-gaap:SellingAndMarketingExpenseMember 2025-01-01 2025-03-31 0001051514 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001051514 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001051514 us-gaap:EmployeeStockOptionMember 2024-12-31 0001051514 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001051514 us-gaap:EmployeeStockOptionMember 2025-03-31 0001051514 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001051514 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001051514 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001051514 sskn:DermatologyRecurringProceduresMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyProceduresEquipmentMember 2024-01-01 2024-03-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyProceduresEquipmentMember 2025-01-01 2025-03-31 0001051514 sskn:DermatologyRecurringProceduresMember us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001051514 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-31 0001051514 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0001051514 sskn:GeographicDistributionOtherForeignMember us-gaap:OperatingSegmentsMember sskn:DermatologyProceduresEquipmentMember 2024-01-01 2024-03-31 0001051514 us-gaap:MiddleEastMember 2024-01-01 2024-03-31 0001051514 country:CN us-gaap:OperatingSegmentsMember sskn:DermatologyProceduresEquipmentMember 2025-01-01 2025-03-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyRecurringProceduresMember country:CN 2024-01-01 2024-03-31 0001051514 country:US sskn:DermatologyProceduresEquipmentMember us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001051514 country:US 2025-01-01 2025-03-31 0001051514 us-gaap:MiddleEastMember us-gaap:OperatingSegmentsMember sskn:DermatologyRecurringProceduresMember 2024-01-01 2024-03-31 0001051514 country:CN 2025-01-01 2025-03-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyRecurringProceduresMember sskn:GeographicDistributionOtherForeignMember 2025-01-01 2025-03-31 0001051514 country:CN sskn:DermatologyRecurringProceduresMember us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001051514 sskn:DermatologyProceduresEquipmentMember sskn:GeographicDistributionOtherForeignMember us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001051514 country:US us-gaap:OperatingSegmentsMember sskn:DermatologyRecurringProceduresMember 2024-01-01 2024-03-31 0001051514 sskn:GeographicDistributionOtherForeignMember 2024-01-01 2024-03-31 0001051514 sskn:DermatologyProceduresEquipmentMember us-gaap:OperatingSegmentsMember country:US 2024-01-01 2024-03-31 0001051514 sskn:DermatologyProceduresEquipmentMember us-gaap:OperatingSegmentsMember country:CN 2024-01-01 2024-03-31 0001051514 sskn:GeographicDistributionOtherForeignMember 2025-01-01 2025-03-31 0001051514 us-gaap:MiddleEastMember us-gaap:OperatingSegmentsMember sskn:DermatologyProceduresEquipmentMember 2025-01-01 2025-03-31 0001051514 country:US 2024-01-01 2024-03-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyRecurringProceduresMember country:US 2025-01-01 2025-03-31 0001051514 us-gaap:MiddleEastMember 2025-01-01 2025-03-31 0001051514 country:CN 2024-01-01 2024-03-31 0001051514 sskn:DermatologyRecurringProceduresMember us-gaap:OperatingSegmentsMember sskn:GeographicDistributionOtherForeignMember 2024-01-01 2024-03-31 0001051514 us-gaap:MiddleEastMember sskn:DermatologyRecurringProceduresMember us-gaap:OperatingSegmentsMember 2025-01-01 2025-03-31 0001051514 us-gaap:MiddleEastMember sskn:DermatologyProceduresEquipmentMember us-gaap:OperatingSegmentsMember 2024-01-01 2024-03-31 0001051514 sskn:DermatologyRecurringProceduresMember us-gaap:OperatingSegmentsMember 2025-03-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyRecurringProceduresMember 2024-12-31 0001051514 us-gaap:OperatingSegmentsMember sskn:DermatologyProceduresEquipmentMember 2025-03-31 0001051514 sskn:DermatologyProceduresEquipmentMember us-gaap:OperatingSegmentsMember 2024-12-31 0001051514 us-gaap:MaterialReconcilingItemsMember 2025-03-31 0001051514 us-gaap:MaterialReconcilingItemsMember 2024-12-31 0001051514 us-gaap:NonUsMember 2024-12-31 0001051514 us-gaap:NonUsMember 2025-03-31 0001051514 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember sskn:TwoCustomersMember 2025-01-01 2025-03-31 0001051514 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember sskn:CustomerOneMember 2024-01-01 2024-03-31 0001051514 us-gaap:OtherCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001051514 us-gaap:OtherCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001051514 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember sskn:TwoCustomersMember 2024-01-01 2024-12-31 0001051514 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember sskn:TwoCustomersMember 2024-12-31 0001051514 us-gaap:AccountsReceivableMember us-gaap:OtherCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-12-31 0001051514 sskn:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-03-31 0001051514 us-gaap:AccountsReceivableMember us-gaap:OtherCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-03-31 0001051514 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember us-gaap:OtherCustomerMember 2024-01-01 2024-12-31 0001051514 us-gaap:AccountsReceivableMember us-gaap:OtherCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001051514 sskn:TwoCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001051514 sskn:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-03-31 0001051514 sskn:AssessmentOneMember sskn:TaxPeriodFromMarch2014ThroughNovember2022Member 2025-01-01 2025-03-31 0001051514 sskn:TaxPeriodFromJune2018ThroughJune2022Member 2025-01-01 2025-03-31 0001051514 sskn:TaxPeriodFromMarch2014ThroughNovember2022Member sskn:AssessmentOneMember 2025-03-31 0001051514 sskn:AssessmentTwoMember sskn:TaxPeriodFromMarch2014ThroughNovember2022Member 2025-03-31 0001051514 sskn:TaxPeriodFromMarch2014ThroughNovember2022Member 2024-10-22 2024-10-22 0001051514 sskn:TaxPeriodFromMarch2014ThroughNovember2022Member 2025-03-31 0001051514 sskn:TheraClearCorporationMember srt:MaximumMember 2022-01-31 0001051514 sskn:TheravantDevelopmentAgreementMember srt:MaximumMember 2022-01-31 0001051514 sskn:TheraClearCorporationMember 2022-01-31 0001051514 us-gaap:GeographicDistributionDomesticMember sskn:TheraClearCorporationMember srt:MinimumMember 2022-01-01 2022-01-31 0001051514 sskn:TheraClearCorporationMember srt:MaximumMember us-gaap:GeographicDistributionDomesticMember 2022-01-01 2022-01-31 0001051514 sskn:TheraClearCorporationMember us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-01-31 0001051514 sskn:TheraClearCorporationMember 2025-01-01 2025-03-31 0001051514 sskn:TheravantDevelopmentAgreementMember 2025-03-31 0001051514 sskn:TheravantDevelopmentAgreementMember srt:MaximumMember 2022-01-02 2022-01-31 0001051514 sskn:TheravantDevelopmentAgreementMember srt:MaximumMember 2025-01-01 2025-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares sskn:Systems xbrli:pure sskn:Payment sskn:Segment sskn:Customer sskn:Device

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2025
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 0-51481
STRATA SKIN SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware |  | 13-3986004
(State or Other Jurisdiction of incorporation or Organization) |  | (I.R.S. Employer Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania |  | 19044
(Address of principal executive offices) |  | (Zip code)

Registrant’s telephone number, including area code: (215) 619-3200
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class |  | Trading Symbol(s) |  | Name Of Each Exchange On Which Registered
Common Stock, $0.001 Par Value |  | SSKN |  | The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ | Smaller reporting company ☒
|  |  | Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares outstanding of our common stock as of May 12, 2025 was 4,171,161 shares.

STRATA SKIN SCIENCES, INC.
TABLE OF CONTENTS

| Page
Part I. | FINANCIAL INFORMATION |
Item 1. | Financial Statements: |
| Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024 | 1
| Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2025 and 2024 (unaudited) | 2
| Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2025 and 2024 (unaudited) | 3
| Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024 (unaudited) | 4
| Notes to Condensed Consolidated Financial Statements (unaudited) | 5
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21
Item 3. | Quantitative and Qualitative Disclosure about Market Risk | 29
Item 4. | Controls and Procedures | 29
Part II. | OTHER INFORMATION |
Item 1. | Legal Proceedings | 30
Item 1A. | Risk Factors | 30
Item 5. | Other Information | 30
Item 6. | Exhibits | 31
| Signatures | 32
| Certifications |

Table of Contents
PART I - Financial Information

ITEM 1. | Financial Statements

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)

|  | March 31, 2025 |  |  | December 31, 2024 |
|  | (unaudited) |  |  |  |
Assets |  |  |  |  |  |
Current assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 6,512 |  |  | $ | 7,261 |
Restricted cash |  |  | 1,334 |  |  |  | 1,334 |
Accounts receivable, net of allowance for credit losses of $548 and $433 at March 31, 2025 and December 31, 2024, respectively |  |  | 5,007 |  |  |  | 5,253 |
Inventories |  |  | 2,659 |  |  |  | 2,246 |
Prepaid expenses and other current assets |  |  | 364 |  |  |  | 501 |
Total current assets |  |  | 15,876 |  |  |  | 16,595 |
Property and equipment, net |  |  | 9,462 |  |  |  | 10,061 |
Operating lease right-of-use assets |  |  | 1,179 |  |  |  | 1,264 |
Intangible assets, net |  |  | 4,856 |  |  |  | 5,348 |
Goodwill |  |  | 2,658 |  |  |  | 2,658 |
Other assets |  |  | 231 |  |  |  | 231 |
Total assets |  | $ | 34,262 |  |  | $ | 36,157 |
Liabilities and Stockholders’ Equity |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 2,816 |  |  | $ | 2,433 |
Accrued expenses and other current liabilities |  |  | 8,779 |  |  |  | 8,593 |
Deferred revenues |  |  | 2,204 |  |  |  | 2,241 |
Current portion of operating lease liabilities |  |  | 331 |  |  |  | 328 |
Current portion of contingent consideration |  |  | 1,009 |  |  |  | 1,030 |
Total current liabilities |  |  | 15,139 |  |  |  | 14,625 |
Long-term debt, net |  |  | 15,231 |  |  |  | 15,192 |
Deferred revenues and other liabilities |  |  | 292 |  |  |  | 353 |
Operating lease liabilities, net of current portion |  |  | 835 |  |  |  | 919 |
Contingent consideration, net of current portion |  |  | 96 |  |  |  | 96 |
Total liabilities |  |  | 31,593 |  |  |  | 31,185 |
Commitments and contingencies (Note 13) |  |  |  |  |  |  |  |
Stockholders’ equity: |  |  |  |  |  |  |  |
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding |  |  | — |  |  |  | — |
Common stock, $0.001 par value; 150,000,000 shares authorized; 4,171,161 shares issued and outstanding at both March 31, 2025 and December 31, 2024 |  |  | 4 |  |  |  | 4 |
Additional paid-in capital |  |  | 253,241 |  |  |  | 253,112 |
Accumulated deficit |  |  | (250,576 | ) |  |  | (248,144 | )
Total stockholders’ equity |  |  | 2,669 |  |  |  | 4,972 |
Total liabilities and stockholders’ equity |  | $ | 34,262 |  |  | $ | 36,157 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
1

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Revenues, net |  | $ | 6,812 |  |  | $ | 6,754 |
Cost of revenues |  |  | 3,165 |  |  |  | 3,674 |
Gross profit |  |  | 3,647 |  |  |  | 3,080 |
Operating expenses: |  |  |  |  |  |  |  |
Engineering and product development |  |  | 96 |  |  |  | 241 |
Selling and marketing |  |  | 2,993 |  |  |  | 3,018 |
General and administrative |  |  | 2,573 |  |  |  | 2,710 |
Total operating expenses |  |  | 5,662 |  |  |  | 5,969 |
Loss from operations |  |  | (2,015 | ) |  |  | (2,889 | )
Other income (expense): |  |  |  |  |  |  |  |
Interest expense |  |  | (486 | ) |  |  | (524 | )
Interest income |  |  | 69 |  |  |  | 45 |
Total other expense |  |  | (417 | ) |  |  | (479 | )
Net loss |  | $ | (2,432 | ) |  | $ | (3,368 | )
Net loss per share of common stock, basic and diluted |  | $ | (0.58 | ) |  | $ | (0.96 | )
Weighted average shares of common stock outstanding, basic and diluted |  |  | 4,171,161 |  |  |  | 3,506,025 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
2

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Changes in Stockholders’ Equity
For The Three Months Ended March 31, 2025 and 2024
(in thousands, except share data)
(unaudited)

|  | Common Stock |  |  |  |  |  |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Additional Paid-in-Capital |  |  | Accumulated Deficit |  |  | Total Stockholders’ Equity |
Balance at January 1, 2025 |  |  | 4,171,161 |  |  | $ | 4 |  |  | $ | 253,112 |  |  | $ | (248,144 | ) |  | $ | 4,972 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | 129 |  |  |  | — |  |  |  | 129 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,432 | ) |  |  | (2,432 | )
Balance at March 31, 2025 |  |  | 4,171,161 |  |  | $ | 4 |  |  | $ | 253,241 |  |  | $ | (250,576 | ) |  | $ | 2,669 |

|  | Common Stock |  |  |  |  |  |  |  |  |  |
|  | Shares |  |  | Amount |  |  | Additional Paid-in-Capital |  |  | Accumulated Deficit |  |  | Total Stockholders’ Equity |
Balance at January 1, 2024 |  |  | 3,506,025 |  |  | $ | 4 |  |  | $ | 250,742 |  |  | $ | (238,058 | ) |  | $ | 12,688 |
Stock-based compensation expense |  |  | — |  |  |  | — |  |  |  | 112 |  |  |  | — |  |  |  | 112 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,368 | ) |  |  | (3,368 | )
Balance at March 31, 2024 |  |  | 3,506,025 |  |  | $ | 4 |  |  | $ | 250,854 |  |  | $ | (241,426 | ) |  | $ | 9,432 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
3

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Cash flows from operating activities: |  |  |  |  |  |
Net loss |  | $ | (2,432 | ) |  | $ | (3,368 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 1,220 |  |  |  | 1,249 |
Amortization of operating lease right-of-use assets |  |  | 85 |  |  |  | 95 |
Amortization of deferred financing costs and debt discount |  |  | 39 |  |  |  | 31 |
Provision for credit losses |  |  | 110 |  |  |  | 84 |
Stock-based compensation expense |  |  | 129 |  |  |  | 112 |
Loss on disposal of property and equipment |  |  | 34 |  |  |  | 13 |
Inventory write-off |  |  | — |  |  |  | 141 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable |  |  | 136 |  |  |  | 726 |
Inventories |  |  | (377 | ) |  |  | (154 | )
Prepaid expenses and other assets |  |  | 137 |  |  |  | (31 | )
Accounts payable |  |  | 362 |  |  |  | 261 |
Accrued expenses and other liabilities |  |  | 169 |  |  |  | (57 | )
Deferred revenues |  |  | (81 | ) |  |  | 194 |
Operating lease liabilities |  |  | (81 | ) |  |  | (100 | )
Net cash used in operating activities |  |  | (550 | ) |  |  | (804 | )
Cash flows from investing activities: |  |  |  |  |  |  |  |
Purchase of property and equipment |  |  | (199 | ) |  |  | (725 | )
Net cash used in investing activities |  |  | (199 | ) |  |  | (725 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Payment of contingent consideration |  |  | — |  |  |  | (18 | )
Net cash used in financing activities |  |  | — |  |  |  | (18 | )
Net decrease in cash, cash equivalents and restricted cash |  |  | (749 | ) |  |  | (1,547 | )
Cash, cash equivalents and restricted cash at beginning of period |  |  | 8,595 |  |  |  | 8,118 |
Cash, cash equivalents and restricted cash at end of period |  | $ | 7,846 |  |  | $ | 6,571 |
Cash and cash equivalents |  | $ | 6,512 |  |  | $ | 5,237 |
Restricted cash |  |  | 1,334 |  |  |  | 1,334 |
Total cash, cash equivalents and restricted cash |  | $ | 7,846 |  |  | $ | 6,571 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |  |  |
Cash paid during the year for interest |  | $ | 450 |  |  | $ | 480 |
Supplemental schedule of non-cash operating, investing and financing activities: |  |  |  |  |  |  |  |
Operating lease right-of-use assets obtained in exchange for operating lease liabilities |  | $ | — |  |  | $ | 977 |
Transfer of property and equipment to inventories |  | $ | 36 |  |  | $ | 9 |
Accrued payment of contingent consideration |  | $ | 21 |  |  | $ | 6 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
4

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 1
The Company:
Background
STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear® Acne Therapy System to broaden its opportunities with expansion potential in the acne care market. The Company markets the device under the brand name TheraClear® X.
The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC excimer laser system received clearance from the United States Food and Drug Administration (the “FDA”) in 2000. As of March 31, 2025, there were 846 XTRAC systems placed in dermatologists’ offices in the United States and 50 systems internationally under the Company’s recurring revenue business model. The XTRAC systems deployed under the recurring revenue model generate revenue on a per procedure basis or include a fixed payment over an agreed upon period with a capped number of treatments which, if exceeded, would incur additional fees. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer, which includes system maintenance and other services. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with a lamp system.
The Pharos excimer laser system holds FDA clearance to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma.
The TheraClear® Acne Therapy System (“TheraClear”) combines intense pulsed light with vacuum (suction) for the treatment of mild to moderate inflammatory acne (including acne vulgaris), comedonal acne and pustular acne.
The Company has signed distributor contracts by year as follows: 2019 – Korea, 2020 – Japan, 2021 – China, Israel, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain, UAE, Jordan and Iraq, and 2023 – Mexico and India. We have renewed and/or amended several of these agreements as required to keep their terms current.
Post-COVID-19 Pandemic
Since March 2020, the global pandemic related to a new strain of coronavirus (“COVID-19”) has negatively impacted business conditions in the industry in which the Company operates, disrupted global supply chains, constrained workforce participation and created significant volatility and disruption of financial markets. The pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices, which are the Company’s primary customers. While most physician offices have reopened, some of the Company’s partner physician practices closed permanently. Accordingly, the COVID-19 pandemic and its variants have negatively impacted the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames and those of its primary customers. It has also negatively impacted the Company’s supply chains and transport, customer behavior and staffing.
Impact of Russia-Ukraine War
Prior to the outbreak of the Russia-Ukraine War, Ukraine was the largest exporter of noble gases including neon, krypton, and xenon and has historically been the source of a significant amount of gas supplied to the Company by its contract suppliers. Neon gas is essential to the proper functioning of the Company’s lasers. The Company’s suppliers have been resourceful in continuing to supply gases to the Company but cannot assure the Company that the supply will remain uninterrupted. The reduced supply and ongoing conflict have also impacted the price of gas worldwide. Additionally, the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 has led to a further tightening of rare gas supplies as semiconductor chip manufacturers reconfigure their supply chains to address the need to secure their own supplies of rare gases for use in the manufacture of computer chips.
5

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Impact of Middle East Conflict
The Company has not seen an impact on its distributors’ businesses in the Middle East due to the Middle East conflict, but cannot predict the impact should the conflict continue or develop into a larger war.
Basis of presentation:
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned, inactive subsidiary in India. All significant intercompany balances and transactions have been eliminated in consolidation.
Unaudited Interim Condensed Consolidated Financial Statements
The accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. These condensed consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed consolidated balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date. Operating results and cash flows for the three months ended March 31, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2025 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”), and other forms filed with the SEC from time to time.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation, including the presentation of foreign revenues within the Company’s business and geographical reporting segment disclosures. These reclassifications had no impact on the previously reported total foreign revenues by reporting segment in the condensed consolidated financial statements.
Significant Accounting Policies
The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the Company’s 2024 Form 10-K, and there have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2025.
Reverse Stock Split
On October 26, 2023, the stockholders of the Company authorized the Board of Directors to effect a reverse stock split of all outstanding shares of common stock. On April 26, 2024, the Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-ten shares, which became effective on June 6, 2024. The Company’s outstanding stock-based awards, including options, restricted stock units and warrants, were also adjusted to reflect the one-for-ten reverse stock split of the Company’s common stock. Outstanding stock-based award units were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity. No fractional shares were issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to a fractional share of common stock were instead entitled to receive a proportional cash payment. The reverse stock split did not change the par value or authorized number of shares of common stock. All share and per share amounts in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company’s significant estimates and judgments include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of contingent consideration, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.
6

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Fair Value Measurements
The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

| • | Level 1 – quoted market prices in active markets for identical assets or liabilities.
| • | Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
| • | Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

The fair values of cash and cash equivalents and restricted cash are based on their respective demand values, which are equal to the carrying values. The carrying values of all short-term monetary assets and liabilities are estimated to approximate their fair values due to the short-term nature of these instruments. As of March 31, 2025 and December 31, 2024, the carrying value of the Company’s long-term debt approximated its fair value due to its variable interest rate.
Accrued Warranty Costs
The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold.
The activity in the warranty accrual is summarized as follows (in thousands):

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Balance, beginning of period |  | $ | 315 |  |  | $ | 303 |
Additions |  |  | 32 |  |  |  | 39 |
Expirations and claims satisfied |  |  | (57 | ) |  |  | (64 | )
Total |  |  | 290 |  |  |  | 278 |
Less current portion within accrued expenses and other current liabilities |  |  | (205 | ) |  |  | (175 | )
Balance within deferred revenues and other liabilities |  | $ | 85 |  |  | $ | 103 |

Net Loss Per Share
Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.
7

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

|  | March 31, |
|  | 2025 |  |  | 2024 |
Stock options |  |  | 521,726 |  |  |  | 539,100 |
Common stock warrants |  |  | 80,000 |  |  |  | 80,000 |
Restricted stock units |  |  | 2,265 |  |  |  | 2,265 |
|  |  | 603,991 |  |  |  | 621,365 |

Recent Accounting Pronouncements Not Yet Adopted
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in this ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the effect this ASU will have on its condensed consolidated financial statements and footnote disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expense s, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of operations. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the effect this ASU will have on its condensed consolidated financial statements and footnote disclosures.
Note 2
Liquidity:
The Company has historically experienced recurring losses, has been dependent on raising capital from the sale of securities in order to continue to operate and has been required to restrict cash for potential sales tax liabilities (see Note 13, Commitments and Contingencies). In October 2021, the Company entered into an equity distribution agreement with an investment bank under which the Company may sell up to an additional $8.9 million of its common stock in registered “at-the-market” offerings. Management believes that the Company’s cash and cash equivalents, the anticipated revenues from the sale or use of its products and operating expense management will be sufficient to satisfy the Company’s working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these condensed consolidated financial statements. However, market conditions, including the negative impact of potential future pandemics, the Russia-Ukraine War, the Middle East conflict and changes in U.S. trade policies, on the financial markets, supply chain disruptions, customer behavior, and rising interest rates, could interfere with the Company’s ability to access financing and on favorable terms.
Note 3
Revenue Recognition:
Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.
8

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Revenues from the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

| • | identification of the contract, or contracts, with a customer;
| • | identification of the performance obligations in the contract;
| • | determination of the transaction price;
| • | allocation of the transaction price to the performance obligations in the contract; and
| • | recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.
Revenues from dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, where the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods is transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.
The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements, as of March 31, 2025 (in thousands):

2025 (remaining) |  | $ | 1,300 |
2026 |  |  | 1,530 |
2027 |  |  | 1,201 |
2028 |  |  | 556 |
|  | $ | 4,587 |

9

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Remaining performance obligations related to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties and service contracts but exclude any dermatology procedures equipment accounted for as leases. As of March 31, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $0.4 million and the Company expects to recognize $0.2 million of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.
Contract liabilities primarily relate to extended warranties and service contracts where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of standalone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of March 31, 2025, the $0.2 million of short-term contract liabilities is presented as deferred revenues and the $0.2 million of long-term contract liabilities is presented within deferred revenues and other liabilities on the condensed consolidated balance sheet. For each of the three months ended March 31, 2025 and 2024, the Company recognized $0.1 million as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2024 and 2023.
With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.
Note 4
Inventories:
Inventories consist of the following (in thousands):

|  | March 31, 2025 |  |  | December 31, 2024 |
Raw materials and work-in-process |  | $ | 2,500 |  |  | $ | 2,041 |
Finished goods |  |  | 159 |  |  |  | 205 |
|  | $ | 2,659 |  |  | $ | 2,246 |

Work-in-process inventories are immaterial, given the Company’s typically short manufacturing cycle, and are included with raw materials inventories.
Due to the expiration of extended warranty service contracts that were assumed in August 2021 in connection with the acquisition of Pharos laser system products, the Company wrote off $0.1 million of inventories that will no longer be needed for warranty purposes during the three months ended March 31, 2024, which is included in cost of revenues in the condensed consolidated statement of operations.
10

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 5
Property and Equipment, net:
Property and equipment consist of the following (in thousands):

|  | March 31, 2025 |  |  | December 31, 2024 |
Lasers placed-in-service |  | $ | 33,984 |  |  | $ | 33,489 |
Equipment, computer hardware and software |  |  | 300 |  |  |  | 300 |
Furniture and fixtures |  |  | 240 |  |  |  | 240 |
Leasehold improvements |  |  | 146 |  |  |  | 87 |
Lasers-in-process |  |  | 1,502 |  |  |  | 2,093 |
|  |  | 36,172 |  |  |  | 36,209 |
Less: accumulated depreciation and amortization |  |  | (26,710 | ) |  |  | (26,148 | )
|  | $ | 9,462 |  |  | $ | 10,061 |

The Company recorded depreciation and amortization expense of $0.7 million and $0.8 million during the three months ended March 31, 2025 and 2024, respectively.
Note 6
Intangible Assets, net:
Intangible assets consist of the following (in thousands):

March 31, 2025 |  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Book Value |
Core technology |  | $ | 5,700 |  |  | $ | (5,557 | ) |  | $ | 143 |
Product technology |  |  | 4,808 |  |  |  | (4,013 | ) |  |  | 795 |
Customer relationships |  |  | 6,900 |  |  |  | (6,728 | ) |  |  | 172 |
Tradenames |  |  | 1,500 |  |  |  | (1,463 | ) |  |  | 37 |
Pharos customer lists |  |  | 5,314 |  |  |  | (1,605 | ) |  |  | 3,709 |
|  | $ | 24,222 |  |  | $ | (19,366 | ) |  | $ | 4,856 |

December 31, 2024 |  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Book Value |
Core technology |  | $ | 5,700 |  |  | $ | (5,415 | ) |  | $ | 285 |
Product technology |  |  | 4,808 |  |  |  | (3,984 | ) |  |  | 824 |
Customer relationships |  |  | 6,900 |  |  |  | (6,555 | ) |  |  | 345 |
Tradenames |  |  | 1,500 |  |  |  | (1,425 | ) |  |  | 75 |
Pharos customer lists |  |  | 5,314 |  |  |  | (1,495 | ) |  |  | 3,819 |
|  | $ | 24,222 |  |  | $ | (18,874 | ) |  | $ | 5,348 |

The Company recorded amortization expense of $0.5 million during each of the three months ended March 31, 2025 and 2024.
Finite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset group may not be recoverable. The Company recognizes an impairment loss when and to the extent that the recoverable amount of an asset group is less than its carrying value. There were no impairment charges for the three months ended March 31, 2025 or 2024.
11

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

2025 (remaining) |  | $ | 774 |
2026 |  | $ | 561 |
2027 |  | $ | 561 |
2028 |  | $ | 561 |
2029 |  | $ | 561 |

Note 7
Accrued Expenses and Other Current Liabilities:
Accrued expenses and other current liabilities consist of the following (in thousands):

|  | March 31, 2025 |  |  | December 31, 2024 |
Warranty obligations |  | $ | 205 |  |  | $ | 213 |
Compensation and related benefits |  |  | 1,984 |  |  |  | 1,781 |
State sales, use and other taxes |  |  | 6,333 |  |  |  | 6,371 |
Professional fees and other |  |  | 257 |  |  |  | 228 |
|  | $ | 8,779 |  |  | $ | 8,593 |

Note 8
Long-Term Debt:
On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust (“MidCap”), also acting as the administrative agent, and the lenders identified therein. The original terms provided for an $8.0 million senior term loan. Borrowings under the senior term loan originally bore interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and were scheduled to mature on September 1, 2026, unless terminated earlier. The Company was obligated to make monthly interest-only payments through September 30, 2024. The credit and security agreement was amended on January 10, 2022 to provide MidCap’s consent to the TheraClear asset acquisition. On September 6, 2022, the Company amended the facility to transition, upon the cessation of LIBOR, to bear interest at one-month Secured Overnight Financing Rate (“SOFR”), or such other applicable period, plus 0.10%, with a floor of 0.50%.
On June 30, 2023, the Company entered into (a) Amendment No. 3 to the credit and security agreement (the “Third Amendment”); (b) the Amended and Restated Warrant Agreement (the “A&R Warrant”) with MidCap Funding XXVII Trust (together with any registered holder from time to time or any holder of the shares issuable or issued upon the exercise or conversion of the warrant, the “Warrantholder”), which amended and restated the warrant agreement to purchase shares of the common stock of the Company, dated as of September 30, 2021 (the “Prior Warrant”), with the Warrantholder; (c) the Amended and Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”) with the Warrantholder, which amended and restated the registration rights agreement, dated as of September 30, 2021, with the Warrantholder; and (d) a letter agreement (the “Fee Letter Agreement”) with MidCap, as agent.
On February 20, 2024, the Company entered into (a) Amendment No. 4 to the credit and security agreement (the “Fourth Amendment”), which amended the credit and security agreement, and (b) a second amended and restated letter agreement (“Amended Fee Letter Agreement”) with MidCap, as agent.
On March 27, 2024, the Company entered into Amendment No. 5 to the credit and security agreement (the “Fifth Amendment”), which further amended the credit and security agreement (as amended to date, the “Senior Term Facility”) to clarify certain provisions related to the maintenance of cash collateral accounts.
12

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Senior Term Facility provides for a senior secured term loan facility of $20.0 million, of which $8.0 million was drawn by the Company on September 30, 2021 (“Credit Facility #1”), $7.0 million was drawn by the Company on June 30, 2023 (“Credit Facility #2”), and an additional $5.0 million (“Credit Facility #3”) was available to be drawn by the Company if its Dermatology Recurring Procedures Revenue (as defined in the Senior Term Facility) for the preceding 12 calendar months (ending on the last day of the calendar month for which a compliance certificate is delivered) was greater than or equal to $30.0 million (such condition, the “Applicable Funding Condition”). The Company did not meet the Applicable Funding Condition and, accordingly, Credit Facility #3 is no longer available to the Company. All borrowings are secured by substantially all of the Company’s assets.
Borrowings under the Senior Term Facility bear interest at a rate per annum equal to the sum of (a) the greater of (i) the sum of (A) 30-day forward-looking term rate of one month SOFR, as published by CME Group Benchmark Administration Limited, from time to time, plus (B) 0.10%, and (ii) the applicable floor rate of 3.50%, with such sum reset monthly, and (b) 7.50%. The effective interest rate of the Senior Term Facility as of March 31, 2025 was 12.93%. The Company is obligated to make interest-only payments (payable monthly in arrears) through June 1, 2026. Commencing on July 1, 2026 and continuing for the remaining 24 months of the facility, the Company will be required to make monthly interest payments and monthly principal payments based on a straight-line amortization schedule set forth in the Senior Term Facility, subject to certain adjustments as described in the Senior Term Facility. The final maturity date under the Senior Term Facility is June 1, 2028, unless earlier terminated. The Senior Term Facility requires the Company to dedicate 100% of certain insurance proceeds to the prepayment of the outstanding term loan, subject to certain exceptions and net of certain expenses and repayments.
The Company may voluntarily prepay the outstanding term loan under the Senior Term Facility, with such prepayment in an amount of at least $5.0 million, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 4.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment was made within 12 months of February 20, 2024, (ii) 3.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 12 months and 24 months after February 20, 2024, (iii) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after February 20, 2024, or (iv) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made 36 months or more after February 20, 2024 and prior to the maturity date.
The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions, as well as various negative covenants. Further, the Senior Term Facility contains (a) a quarterly financial covenant that requires the Company to not have less than $30.5 million of net revenue (raised to $33.0 million by December 31, 2026 and, for periods ending after December 31, 2026, such net revenue as determined in good faith by MidCap, which shall not be less than the applicable minimum net revenue amount for the immediately preceding period and $33.0 million) for the trailing 12-month period as of March 31, 2025, and (b) a minimum of unrestricted cash (as defined in the Senior Term Facility), at all times, of not less than $3.0 million. At March 31, 2025, the Company was in compliance with all financial covenants within the Senior Term Facility.
Upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, (i) suspend or terminate the term loan commitment and MidCap’s and the other lenders’ obligations with respect thereto, and (ii) by notice to the Company, declare all or any portion of the obligations under the Senior Term Facility to be immediately due and payable. In addition to MidCap’s other rights and available remedies, but subject to applicable cure periods, upon the occurrence and during the continuance of an event of default, MidCap may, and at the direction of a requisite percentage of the lenders must, terminate the Senior Term Facility. At March 31, 2025, no event of default had occurred, and the Company believed that events or conditions having a material adverse effect, giving rise to an acceleration of any amounts outstanding under the Senior Term Facility, had not occurred and were remote.
Pursuant to the Amended Fee Letter Agreement, the Company agreed to pay MidCap, as administrative agent, the following fees: (a) an origination fee on June 30, 2023 in an amount equal to (i) the Credit Extensions (as defined in the Senior Term Facility) in respect of Credit Facility #2, multiplied by (ii) 0.50%; (b) on the maturity date of the Senior Term Facility or any earlier date on which the obligations thereunder become due and payable in full or are otherwise paid in full (such date, the “Full Exit Fee Payment Date”), the Company shall pay an exit fee equal to (i) 4.00% of the total aggregate principal amount of Credit Extensions (as defined in the Senior Term Facility) made pursuant to the Senior Term Facility (regardless of any repayment or prepayment thereof) as of the Full Exit Fee Payment Date (such aggregate amount, the “Exit Fee Base Amount”), less (ii) any Partial Exit Fee (as defined below) previously paid; and (c) on the date of any voluntary or mandatory partial prepayment of the borrowings under the Senior Term Facility (or on the date such mandatory prepayment becomes due and payable) (each such date, a “Partial Exit Fee Payment Date”), the Company shall pay an exit fee equal to 4.00% of the principal amount of the credit facilities paid or prepaid (or required to be paid in the case of a mandatory prepayment) as of the Partial Exit Fee Payment Date (such amount, the “Partial Exit Fee”). The Amended Fee Letter Agreement also provided for an origination fee related to Credit Facility #3, which is no longer payable as the Company did not meet the Applicable Funding Condition as noted above.
13

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Prior Warrant allowed the Warrantholder, an affiliate of the lender, to purchase 37,362 shares of the Company’s common stock at an exercise price equal to $18.20 per share for a 10-year period ending September 30, 2031. Pursuant to, and in accordance with, the terms and conditions of the A&R Warrant, which amended and restated the Prior Warrant, the Warrantholder can purchase 80,000 shares of the Company’s common stock at an exercise price equal to $8.80 per share for a 10-year period ending on June 30, 2033. Pursuant to the A&R Registration Rights Agreement, the Company registered the shares underlying the A&R Warrant effective August 18, 2023. The amendment of the warrant resulted in an increase in the fair value of the warrant, which has been accounted for as a lender fee.
The Fourth Amendment was accounted for as a debt modification, as the new loan is not considered substantially different from the existing loan. In connection with the Fourth Amendment, the Company increased the accrued exit fee, which is recorded as both a debt discount and an increase to the principal amount of debt, to $0.6 million. The debt discount, which also includes third party costs incurred in connection with the Third Amendment of $13.0 thousand, is being recognized as interest expense over the term of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $0.4 million as of March 31, 2025. The Company recognized interest expense of $0.5 million during the three months ended March 31, 2025, of which $39.0 thousand was related to the amortization of the debt discount. The Company recognized interest expense of $0.5 million during the three months ended March 31, 2024, of which $31.0 thousand was related to the amortization of the debt discount.
Future minimum principal payments at March 31, 2025 are as follows (in thousands):

2026 |  | $ | 3,750 |
2027 |  |  | 7,500 |
2028 |  |  | 3,750 |
|  |  | 15,000 |
Exit fee |  |  | 600 |
|  |  | 15,600 |
Less: unamortized debt discount |  |  | (369 | )
Long-term debt, net |  | $ | 15,231 |

Note 9
Stock-Based Compensation:
The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of March 31, 2025, there were 7,270,212 shares of common stock remaining available for issuance for awards under the 2016 Plan.
14

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The Company measures share‑based awards at their grant‑date fair values and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded share‑based compensation expense (for all awards and modifications, if any) in the accompanying condensed consolidated statements of operations as follows (in thousands):

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Selling and marketing* |  | $ | 15 |  |  | $ | (37 | )
General and administrative |  |  | 114 |  |  |  | 149 |
|  | $ | 129 |  |  | $ | 112 |

*Selling and marketing expense was negative during the three months ended March 31, 2024 due to the forfeiture of awards during the period.
Stock Options
The following table summarizes stock option activity for the three months ended March 31, 2025:

|  | Number of Shares Under Option Plan |  |  | Weighted-Average Exercise Price per Option |  |  | Weighted-Average Remaining Contractual Term (in years) |
Outstanding at January 1, 2025 |  |  | 521,726 |  |  | $ | 8.16 |  |  |  |
Granted |  |  | — |  |  | $ | — |  |  |  |
Forfeited and expired |  |  | — |  |  | $ | — |  |  |  |
Outstanding at March 31, 2025 |  |  | 521,726 |  |  | $ | 8.16 |  |  |  | 7.6 |
Exercisable at March 31, 2025 |  |  | 231,467 |  |  | $ | 11.75 |  |  |  | 6.3 |
Vested and expected to vest at March 31, 2025 |  |  | 521,726 |  |  | $ | 8.16 |  |  |  | 7.6 |

As of March 31, 2025, the total unrecognized compensation expense related to unvested stock option awards was $0.9 million, which the Company expects to recognize over a weighted average period of approximately 2.2 years. The options outstanding and exercisable at March 31, 2025 had no intrinsic value.
Restricted Stock Units
Restricted stock units (“RSUs”) have historically been issued to certain board members. As of both March 31, 2025 and January 1, 2025, there were no unvested RSUs. No RSUs were granted, vested or forfeited during the three months ended March 31, 2025.
Note 10
Income Taxes:
The Company accounts for income taxes using the asset and liability method. The provision for income taxes includes federal, state, and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.
No income tax expense was incurred for the three months ended March 31, 2025 and 2024.
15

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 11
Business and Geographical Reporting Segments:
The Company has organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC and TheraClear procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.
Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense) is also not allocated to the operating segments.
The following tables present results of operations from the Company’s business segments for the periods indicated below (in thousands, except gross profit %):

Three Months Ended March 31, 2025 |  | Dermatology Recurring Procedures |  |  | Dermatology Procedures Equipment |  |  | Total |
Revenues, net |  | $ | 4,727 |  |  | $ | 2,085 |  |  | $ | 6,812 |
Cost of revenues |  |  | 2,049 |  |  |  | 1,116 |  |  |  | 3,165 |
Gross profit |  |  | 2,678 |  |  |  | 969 |  |  |  | 3,647 |
Gross profit % |  |  | 56.7 | % |  |  | 46.5 | % |  |  | 53.5 | %
Allocated expenses: |  |  |  |  |  |  |  |  |  |  |  |
Engineering and product development |  |  | 66 |  |  |  | 30 |  |  |  | 96 |
Selling and marketing |  |  | 2,077 |  |  |  | 916 |  |  |  | 2,993 |
Unallocated expenses |  |  | — |  |  |  | — |  |  |  | 2,573 |
Total allocated and unallocated expenses |  |  | 2,143 |  |  |  | 946 |  |  |  | 5,662 |
Income (loss) from operations |  |  | 535 |  |  |  | 23 |  |  |  | (2,015 | )
Interest expense |  |  | — |  |  |  | — |  |  |  | (486 | )
Interest income |  |  | — |  |  |  | — |  |  |  | 69 |
Net income (loss) |  | $ | 535 |  |  | $ | 23 |  |  | $ | (2,432 | )

16

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)

Three Months Ended March 31, 2024 |  | Dermatology Recurring Procedures |  |  | Dermatology Procedures Equipment |  |  | Total |
Revenues, net |  | $ | 4,696 |  |  | $ | 2,058 |  |  | $ | 6,754 |
Cost of revenues |  |  | 2,195 |  |  |  | 1,479 |  |  |  | 3,674 |
Gross profit |  |  | 2,501 |  |  |  | 579 |  |  |  | 3,080 |
Gross profit % |  |  | 53.3 | % |  |  | 28.1 | % |  |  | 45.6 | %
Allocated expenses: |  |  |  |  |  |  |  |  |  |  |  |
Engineering and product development |  |  | 196 |  |  |  | 45 |  |  |  | 241 |
Selling and marketing |  |  | 2,753 |  |  |  | 265 |  |  |  | 3,018 |
Unallocated expenses |  |  | — |  |  |  | — |  |  |  | 2,710 |
Total allocated and unallocated expenses |  |  | 2,949 |  |  |  | 310 |  |  |  | 5,969 |
(Loss) income from operations |  |  | (448 | ) |  |  | 269 |  |  |  | (2,889 | )
Interest expense |  |  | — |  |  |  | — |  |  |  | (524 | )
Interest income |  |  | — |  |  |  | — |  |  |  | 45 |
Net (loss) income |  | $ | (448 | ) |  | $ | 269 |  |  | $ | (3,368 | )

The following table presents depreciation and amortization by reportable segment for the periods indicated below (in thousands):

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Dermatology recurring procedures |  | $ | 1,120 |  |  | $ | 1,114 |
Dermatology procedures equipment |  |  | 100 |  |  |  | 132 |
Unallocated expenses |  |  | — |  |  |  | 3 |
Total |  | $ | 1,220 |  |  | $ | 1,249 |

The following tables present the Company’s revenue disaggregated by geographical region for the periods indicated below (in thousands). Domestic refers to revenue from customers based in the United States, and foreign revenue is derived from the Company’s distributors primarily in Asia.

Three Months Ended March 31, 2025 |  | Dermatology Recurring Procedures |  |  | Dermatology Procedures Equipment |  |  | Total |
Domestic |  | $ | 4,248 |  |  | $ | 149 |  |  | $ | 4,397 |
China |  |  | — |  |  |  | 834 |  |  |  | 834 |
Middle East |  |  | — |  |  |  | 711 |  |  |  | 711 |
Other foreign |  |  | 479 |  |  |  | 391 |  |  |  | 870 |
Total |  | $ | 4,727 |  |  | $ | 2,085 |  |  | $ | 6,812 |

Three Months Ended March 31, 2024 |  | Dermatology Recurring Procedures |  |  | Dermatology Procedures Equipment |  |  | Total |
Domestic |  | $ | 4,320 |  |  | $ | 141 |  |  | $ | 4,461 |
China |  |  | — |  |  |  | 1,102 |  |  |  | 1,102 |
Middle East |  |  | — |  |  |  | 430 |  |  |  | 430 |
Other foreign |  |  | 376 |  |  |  | 385 |  |  |  | 761 |
Total |  | $ | 4,696 |  |  | $ | 2,058 |  |  | $ | 6,754 |

17

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The following table presents total assets by reportable segment (in thousands):

|  | March 31, 2025 |  |  | December 31, 2024 |
Dermatology recurring procedures |  | $ | 20,071 |  |  | $ | 21,750 |
Dermatology procedures equipment |  |  | 5,798 |  |  |  | 5,081 |
Other unallocated assets |  |  | 8,393 |  |  |  | 9,326 |
Total |  | $ | 34,262 |  |  | $ | 36,157 |

Long-lived assets of $1.2 million and $1.3 million were located in international markets, primarily Korea and Japan, as of March 31, 2025 and December 31, 2024, respectively, with the remainder located in domestic markets.
Note 12
Significant Customer Concentrations:
The Company had two customers, international distributors from which the Company primarily earns dermatology procedures equipment revenues, that accounted for 10% or more of the Company’s net revenues for the three months ended March 31, 2025. Revenues from these customers were $1.5 million, or 22.7%. Accounts receivable associated with these customers were $1.2 million, or 24.1%, of net accounts receivable as of March 31, 2025 and $1.3 million, or 25.0%, of net accounts receivable at December 31, 2024. Accounts receivable associated with one other customer which accounted for 10% or more of the Company’s net accounts receivable as of March 31, 2025 and December 31, 2024 was $0.6 million, or 12.0%, and $0.9 million, or 17.2%, of net accounts receivable, respectively.
The Company had one customer, an international distributor from which the Company primarily earns dermatology procedures equipment revenues, that accounted for 10% or more of the Company’s net revenues for the three months ended March 31, 2024. Revenues from this customer were $1.1 million, or 16.3%.
Note 13
Commitments and Contingencies:
Leases
The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than 12 months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from one to five years.
In March 2024, the Company terminated the existing lease for its California facility and concurrently executed a new lease that effectively extended the term of the lease for five years, which has been accounted for as a lease modification. The ROU asset and operating lease liability were remeasured at the modification date, resulting in an increase to both balances of $1.0 million during the three months ended March 31, 2024. There were no lease modifications during the three months ended March 31, 2025.
Operating lease costs were $0.1 million for each of the three months ended March 31, 2025 and 2024. Cash paid for amounts included in the measurement of operating lease liabilities was $0.1 million for each of the three months ended March 31, 2025 and 2024. As of March 31, 2025, the weighted average incremental borrowing rate was 12.29% and the weighted average remaining lease term was 4.0 years.
18

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The following table summarizes the Company’s operating lease maturities as of March 31, 2025 (in thousands):

2025 (remaining) |  | $ | 345 |
2026 |  |  | 334 |
2027 |  |  | 290 |
2028 |  |  | 301 |
2029 |  |  | 232 |
Total remaining lease payments |  |  | 1,502 |
Less: imputed interest |  |  | (336 | )
Total lease liabilities |  | $ | 1,166 |

Accrued State Sales and Use Tax Matters
The Company records state sales tax collected and remitted for its customers on dermatology procedures equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses within the condensed consolidated statements of operations.
The Company believes its state sales and use tax accruals have been properly recognized such that, if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state, the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities, as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing, and time period at issue, as well as the final outcome of any audit and actual settlement, remains uncertain.
In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. The states of New York and California have assessed the Company an aggregate of $5.2 million including penalties and interest. The audits cover the period from March 2014 through November 2022. The Company received notification that an administrative state judge in New York issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. This ruling covers $1.8 million of the total $5.2 million of assessments. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, the Company received a written decision from the State of New York Appeals Tribunal (“Tribunal”) overturning the favorable sales tax determination of the administrative law judge. The Company appealed the Tribunal’s decision to the New York State Appellate Division (“Appellate Division”), and posted the required appellate bond in the form of cash collateral. Oral argument was held by the Appellate Division on January 18, 2024.
On March 8, 2024, the Company received a decision from the Appellate Division ruling against it in the matter of its sales tax appeal, affirming the Tribunal’s ruling that the Company’s sale of XTRAC treatment codes is subject to sales tax. The Appellate Division concluded that, through the usage arrangements, the Company’s customers had possession of the laser devices and had a license and ability to use the laser devices. The Appellate Division also agreed with the Tribunal that the primary function analysis was not applicable in this matter. On April 11, 2024, the Company filed a motion for leave to appeal the Appellate Division’s decision to the New York State Court of Appeals (“Court of Appeals”). On October 22, 2024, in an unsigned one-line decision, the Court of Appeals denied the Company’s motion to appeal the Appellate Division ruling. Therefore, the adverse decision stands and New York will execute on the appellate bond the Company posted for $1.3 million. As of March 31, 2025, the Company has accrued $1.8 million including penalties and interest as a result of the Appellate Division ruling. The Company is in the administrative process of appeal with respect to the remaining $1.3 million of assessments in the State of New York. The Company believes that the Appellate Division ruling provides an avenue for challenging the pending audit periods and subsequent periods, provided the Company can show that the value of the equipment provided to customers is incidental to the overall value of the non-taxable services that are provided, or should be treated similarly to pharmaceutical treatments, which are generally exempt from sales tax.
19

Table of Contents
STRATA Skin Sciences, Inc. and Subsidiary
Notes to Condensed Consolidated Financial Statements
(unaudited)
The State of California has made aggregate assessments of $2.1 million including penalties and interest. The audits cover the period from June 2018 through June 2022. The Company is in the administrative process of appeal in this jurisdiction as well.
In those states where the Company did not or may not prevai l with the defenses it has proposed, and in the event there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine, or the Company does not have other defenses where the Company prevails, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties. The precise scope, timing and time periods at issue, as well as the final outcomes of the investigations and judicial proceedings, remain uncertain. Accordingly, the Company’s estimate may change from time to time, and actual losses could vary.
Contingent Consideration
In connection with the Company’s acquisition of certain assets related to the TheraClear devices in 2022, Theravant Corporation (“Theravant”) is eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones ($1.0 million of which is due upon the earlier of achieving a revenue target or July 2025), up to $20.0 million in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $0.5 million in future milestone payments upon the achievement of certain commercialization related targets. The Company has notified Theravant that it believes the earnout payments are not due and will not be due in the future. Theravant has disputed the Company’s position, and the matter is under discussion among the signatories to the purchase agreement. Through March 31, 2025, the Company has incurred an aggregate of $0.2 million of royalty and gross profit payments based on gross profit from domestic and international sales.
Milestone Payments
In January 2022, the Company entered into a Development Agreement (the “Development Agreement”) with Theravant. Under the Development Agreement, the Company was to reimburse Theravant for costs incurred in further developing certain TheraClear technology and other healthcare products and methods for the medical aesthetic marketplace. In connection with the development of three devices, Theravant was eligible to receive $0.5 million upon FDA clearance for each device and $0.5 million upon achievement of certain net revenue targets for each device, aggregating to $3.0 million of potential future milestone payments under the Development Agreement. The Development Agreement had a three-year term, unless terminated sooner by either party, and expired in January 2025. The Development Agreement was being accounted for separately from the TheraClear asset acquisition. No milestone payments were incurred under the Development Agreement, and the Company does not anticipate that any such payments may be due in the future.
Legal Matters
In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract, and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony, and information in connection with various aspects of its activities.
20

Table of Contents

ITEM 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations provides information about our results of operations, financial condition, liquidity and asset quality. This information is intended to facilitate your understanding and assessment of significant changes and trends related to our financial condition and results of operations. This discussion should be read in conjunction with our financial information in our Annual Report on Form 10-K for the year ended December 31, 2024 (“2024 Form 10-K”), and the unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). This discussion contains forward-looking statements that involve risks and uncertainties. These statements include, but are not limited to, statements about the plans, objectives, expectations and intentions of STRATA Skin Sciences, Inc., a Delaware corporation (referred to in this Report as “we,” “us,” “our,” “STRATA” or “STRATA Skin Sciences”) and can be identified by terminology such as the words “may,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “will,” “could,” “project,” “target,” “potential,” “continue” and similar expressions, and are intended to identify forward-looking statements, as such term is defined in the Private Securities Litigation Reform Act of 1995, and other statements contained in this Report that are not historical facts. Factors that could cause results to differ from those expressed in these forward-looking statements include, but are not limited to, the risks and uncertainties described or referenced in Part I, Item 1A. “Risk Factors,” in the 2024 Form 10-K and in other of our public filings with the SEC, as well as the following:

| • | forecasts of future business performance, consumer trends and macro-economic conditions;

| • | descriptions of market, competitive conditions, and competitive product introductions;

| • | descriptions of plans or objectives of management for future operations, products or services;

| • | actions by the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies with respect to our products or product candidates;

| • | changes to third-party reimbursement of laser treatments using our devices;

| • | our estimates regarding the sufficiency of our cash resources, expenses, capital requirements and needs for additional financing and our ability to obtain additional financing;

| • | our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

| • | anticipated results of existing or future litigation or government actions;

| • | health emergencies, the spread of infectious disease or pandemics; and

| • | descriptions or assumptions underlying or related to any of the above items.

Although we believe that the expectations reflected in forward-looking statements are reasonable, such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These statements, like all statements in this Report, speak only as of their date (unless another date is indicated), and we undertake no obligation to update or revise these statements in light of future developments.
Introduction, Outlook and Overview of Business Operations
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions, as well as the TheraClear® X Acne Therapy System (“TheraClear”) utilized in the treatment of acne-related skin conditions.
21

Table of Contents
The XTRAC ultraviolet light excimer laser system is utilized to treat psoriasis, vitiligo, and other skin diseases. The XTRAC excimer laser system received clearance from the FDA in 2000 and has since become a widely recognized treatment among dermatologists. The system delivers targeted 308nm ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. As of March 31, 2025, there were 846 XTRAC systems placed in dermatologists’ offices in the United States under our dermatology recurring procedures model, a decrease from 864 as of December 31, 2024. Under the dermatology recurring procedures model, the XTRAC system is placed in a physician’s office and fees are charged on a per procedure basis or a fee is charged on a periodic basis not to exceed an agreed upon number of procedures. The XTRAC system’s use for psoriasis is covered by nearly all major insurance companies, including Medicare. The VTRAC Excimer Lamp system, offered internationally in addition to the XTRAC, provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system. The Pharos excimer laser system holds FDA clearance to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis, and leukoderma. We believe there are approximately 8 million people in the United States and up to 125 million people worldwide suffering from psoriasis, and 1% to 2% of the world’s population suffers from vitiligo.
The TheraClear® X Acne Therapy System combines intense pulsed light with vacuum (suction) for the treatment of mild to moderate inflammatory acne (including acne vulgaris), comedonal acne and pustular acne. The TheraClear device was cleared by the FDA through the 510(k) process. Currently, there is little insurance reimbursement coverage for acne treatments, such as those provided by TheraClear.
Our non-U.S. business focuses on a direct distribution model for equipment sales and recurring revenue, and we have distribution agreements in place in the Mid-East, Asia, and Mexico.
Post-COVID-19 Pandemic
In late 2019, there was an outbreak of a new strain of coronavirus (“COVID-19”) which became a global pandemic. Since March 2020, the COVID-19 pandemic has negatively impacted business conditions in the industry in which we operate, disrupted global supply chains, constrained workforce participation, and created significant volatility and disruption of financial markets. The pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices, which are our primary customers. While most physician offices have reopened, some of our partner physician practices closed permanently, and the impact of the COVID-19 pandemic and its variants on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frames is ongoing. We will continue to identify and plan around potential future pandemics and disruptions to our business.
Impact of Russia-Ukraine War
Prior to the outbreak of the Russia-Ukraine War, Ukraine was the largest exporter of noble gases including neon, krypton, and xenon and has historically been the source of a significant amount of gas supplied to us by our contract suppliers. Neon gas is essential to the proper functioning of our lasers. Our suppliers have been resourceful in continuing to supply gases to us but cannot assure us that the supply will not remain uninterrupted. The reduced supply and ongoing conflict have also impacted the price of gas worldwide. Additionally, the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 has led to a further tightening of rare gas supplies as semiconductor chip manufacturers reconfigure their supply chains to address the need to secure their own supplies of rare gases for use in the manufacture of computer chips.
Impact of Middle East Conflict
We have not seen an impact on our distributors’ businesses in the Middle East due to the Middle East conflict, but cannot predict the impact should the conflict continue or develop into a larger war.
Key Technologies

| • | XTRAC® Excimer Laser. XTRAC received FDA clearance in 2000 and has since become a widely recognized treatment among dermatologists for psoriasis and other skin diseases. The XTRAC System delivers ultra-narrowband ultraviolet B (“UVB”) light to affected areas of skin. Following a series of treatments typically performed twice weekly, psoriasis remission can be achieved, and vitiligo patches can be re-pigmented. XTRAC is endorsed by the National Psoriasis Foundation, and its use for psoriasis is covered by nearly all major insurance companies, including Medicare. We estimate that more than half of all major insurance companies now offer reimbursement for vitiligo as well.

22

Table of Contents

| • | In the third quarter of 2018, we announced the FDA granted clearance for our Multi Micro Dose (MMD) tip for our XTRAC excimer laser. The MMD Tip accessory is indicated for use in conjunction with the XTRAC laser system to filter the Narrow Band UVB (“NB-UVB”) light at delivery in order to calculate and individualize the maximum non-blistering dose for a particular patient.

| • | In January 2020, we announced the FDA granted clearance of our XTRAC Momentum Excimer Laser Platform. In February 2022, we announced the commercial launch, with the first installation in the U.S. market, of our next generation excimer laser system, XTRAC Momentum® 1.0.

| • | VTRAC® Lamp. VTRAC received FDA clearance in 2005 and provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.

| • | TheraClear® X Acne Treatment Device. The TheraClear® Acne Therapy System combines intense pulsed light with vacuum (suction) for the treatment of mild to moderate inflammatory acne (including acne vulgaris), comedonal acne and pustular acne.

Critical Accounting Estimates
The preparation of our financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the SEC requires us to make estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates and assumptions on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although we believe our estimates and assumptions are reasonable when made, they are based upon information available to us at the time they are made. We evaluate our estimates and assumptions on an ongoing basis and, if necessary, make adjustments. Due to the risks and uncertainties involved in our business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.
We define our critical accounting estimates as those accounting policies that are most important to the portrayal of our financial condition and results of operations and require our most difficult and subjective judgments. Critical accounting estimates made in accordance with such policies are regularly discussed with our Audit Committee. Those policies are discussed under “Critical Accounting Policies and Estimates,” as well as in our consolidated financial statements and the footnotes thereto, included in the 2024 Form 10-K, and include revenue recognition, contingent consideration, goodwill and intangible impairments, and sales and use taxes. There have been no changes to our critical accounting policies in the three months ended March 31, 2025.
Results of Operations
Revenues
The following table presents revenues from our two business segments for the periods presented below (in thousands):

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Dermatology recurring procedures |  | $ | 4,727 |  |  | $ | 4,696 |
Dermatology procedures equipment |  |  | 2,085 |  |  |  | 2,058 |
Total revenues |  | $ | 6,812 |  |  | $ | 6,754 |

23

Table of Contents
Dermatology Recurring Procedures
Recognized recurring treatment revenue for the three months ended March 31, 2025 was $4.7 million, which we estimate is approximately 54,000 XTRAC treatments with prices between $65 to $95 per treatment, compared to recognized recurring treatment revenue for the three months ended March 31, 2024 of $4.7 million, which we estimate is approximately 65,000 XTRAC treatments with prices between $65 to $95 per treatment. Subsequent to the launch of the TheraClear Acne Therapy System, there were 160 and 104 TheraClear devices placed in dermatologists’ offices in the United States under our recurring procedures model as of March 31, 2025 and 2024, respectively.
Increases in procedures are dependent upon building market acceptance through marketing programs with our physician partners and their patients to show that the XTRAC procedures will be of clinical benefit and will be generally reimbursed by insurers. We believe that several factors have an impact on the prescribed use of XTRAC treatments for psoriasis and vitiligo patients. Specifically, we believe that there is a lack of awareness of the positive effects of XTRAC treatments among both sufferers and providers; and the treatment regimen, which can sometimes require up to 12 or more treatments, has limited XTRAC use to certain patient populations. We reduced our direct-to-patient advertising over the course of 2023, which we believe contributed to a reduction in the number of XTRAC treatments compared to prior periods that continued into 2024. Therefore, our strategy going forward is to continue to increase our direct-to-patient program for XTRAC advertising in the United States, targeting psoriasis and vitiligo patients through a variety of media and through our use of social media such as Facebook and X (formerly Twitter), and aimed at motivating them to seek out XTRAC treatments from our physician partners. We monitor the results of our advertising expenditures in this area in order to effectively reach the more than 10 million patients in the United States we believe are afflicted with these diseases.
Revenues from dermatology recurring procedures are recognized over the estimated usage period of the agreed upon number of treatments, as the treatments are being used. As of March 31, 2025 and 2024, we deferred domestic net revenues of $1.6 million and $1.9 million, respectively, which will be recognized as revenue over the remaining usage period for the related placements. Less revenue from the first quarter of 2025 was deferred into the second quarter of 2025, which positively impacted that quarter, as compared to the first quarter of 2024, when more revenue from that quarter was deferred into the second quarter of 2024.
Dermatology Procedures Equipment
For the three months ended March 31, 2025, dermatology procedures equipment revenues were $2.1 million. Internationally, we sold 18 systems (15 XTRAC and three VTRAC) during the three months ended March 31, 2025. Domestically, there were no XTRAC systems sold during the three months ended March 31, 2025.
For the three months ended March 31, 2024, dermatology procedures equipment revenues were $2.1 million. Internationally, we sold 16 systems (13 XTRAC and three VTRAC) during the three months ended March 31, 2024. Domestically, we sold one XTRAC system during the three months ended March 31, 2024. In addition to equipment sales, we recognized approximately $30.0 thousand of previously deferred service revenue associated with assumed service contracts in connection with the Pharos asset acquisition during the three months ended March 31, 2024.
Cost of Revenues
The following table presents cost of revenues from our two business segments for the periods listed below (in thousands):

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Dermatology recurring procedures |  | $ | 2,049 |  |  | $ | 2,195 |
Dermatology procedures equipment |  |  | 1,116 |  |  |  | 1,479 |
Total cost of revenues |  | $ | 3,165 |  |  | $ | 3,674 |

24

Table of Contents
Gross Profit Analysis
The following table presents changes in our gross profit for the periods presented below:
Company Profit Analysis

|  | Three Months Ended March 31, |
(in thousands, except percentages) |  | 2025 |  |  | 2024 |
Revenues, net |  | $ | 6,812 |  |  | $ | 6,754 |
Cost of revenues |  |  | 3,165 |  |  |  | 3,674 |
Gross profit |  | $ | 3,647 |  |  | $ | 3,080 |
Gross profit percentage |  |  | 53.5 | % |  |  | 45.6 | %

Gross profit increased to $3.6 million for the three months ended March 31, 2025 from $3.1 million during the same period in 2024. As a percentage of revenues, gross profit was 53.5% for the three months ended March 31, 2025, as compared to 45.6% for the same period in 2024. The increase in gross profit percentage compared to the same period in the prior year was primarily the result of our use of refurbished parts, which have a lower cost of revenues than new parts, in connection with our stated plan to remove devices from underperforming accounts and refurbish those devices for future repairs use, and the write-off of inventories in 2024 related to the Pharos laser system products that will no longer be needed for warranty purposes due to the expiration of the related warranty service contracts during the three months ended March 31, 2024.
Dermatology Recurring Procedures

|  | Three Months Ended March 31, |
(in thousands, except percentages) |  | 2025 |  |  | 2024 |
Revenues, net |  | $ | 4,727 |  |  | $ | 4,696 |
Cost of revenues |  |  | 2,049 |  |  |  | 2,195 |
Gross profit |  | $ | 2,678 |  |  | $ | 2,501 |
Gross profit percentage |  |  | 56.7 | % |  |  | 53.3 | %

Gross profit for dermatology recurring procedures increased to $2.7 million for the three months ended March 31, 2025 from $2.5 million during the same period in 2024. As a percentage of revenues, gross profit was 56.7% for the three months ended March 31, 2025, as compared to 53.3% for the same period in 2024. The increase in gross profit percentage compared to the same period in the prior year was primarily the result of our use of refurbished parts, which have a lower cost of revenues than new parts, in connection with our stated plan to remove devices from underperforming accounts and refurbish those devices for future repairs use.
Dermatology Procedures Equipment

|  | Three Months Ended March 31, |
(in thousands, except percentages) |  | 2025 |  |  | 2024 |
Revenues, net |  | $ | 2,085 |  |  | $ | 2,058 |
Cost of revenues |  |  | 1,116 |  |  |  | 1,479 |
Gross profit |  | $ | 969 |  |  | $ | 579 |
Gross profit percentage |  |  | 46.5 | % |  |  | 28.1 | %

25

Table of Contents
Gross profit for dermatology procedures equipment increased to $1.0 million for the three months ended March 31, 2025 from $0.6 million during the same period in 2024. As a percentage of revenues, gross profit was 46.5% for the three months ended March 31, 2025, as compared to 28.1% for the same period in 2024. The increase in gross profit percentage compared to the same period in the prior year was primarily the result of the write-off of inventories related to the Pharos laser system products that will no longer be needed for warranty purposes due to the expiration of the related warranty service contracts during the three months ended March 31, 2024 and a discount on the sale of certain lasers to an international distributor during the three months ended March 31, 2024.
Engineering and Product Development
For the three months ended March 31, 2025, engineering and product development expenses were $0.1 million as compared to $0.2 million for the three months ended March 31, 2024. Engineering and product development costs were lower during the three-month period in 2025 primarily as a result of a decrease in salaries and outside services.
Selling and Marketing Expenses
For each of the three months ended March 31, 2025 and 2024, selling and marketing expenses were $3.0 million, with a decrease in employee related expenses offset by an increase in expenses related to our direct-to-patient advertising campaign aimed at motivating psoriasis and vitiligo patients to seek out XTRAC treatments from our physician partners.
General and Administrative Expenses
For the three months ended March 31, 2025, general and administrative expenses were $2.6 million as compared to $2.7 million for the three months ended March 31, 2024. General and administrative expenses were lower during the three-month period in 2025 primarily as a result of a decrease in salaries and compensation related expenses.
Interest Expense
For each of the three months ended March 31, 2025 and 2024, interest expense was $0.5 million, as there was no significant change in the principal balance or interest rate associated with our Senior Term Facility.
Non-GAAP Financial Measures
We have determined to supplement our condensed consolidated financial statements, prepared in accordance with U.S. GAAP, presented elsewhere within this Report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP adjusted EBITDA, “Earnings Before Interest, Taxes, Depreciation, and Amortization.”
This non-GAAP disclosure has limitations as an analytical tool, should not be viewed as a substitute for Net Earnings (Loss) determined in accordance with U.S. GAAP, and should not be considered in isolation or as a substitute for analysis of the Company’s results as reported under U.S. GAAP, nor is it necessarily comparable to non-GAAP performance measures that may be presented by other companies. We consider these non-GAAP measures in addition to our results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers’ overall understanding of our current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that our future results will be unaffected by similar adjustments to Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, we believe the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains and losses that may not be indicative of our core operating results and business outlook. In addition, we believe non-GAAP measures enhance the comparability of results against prior periods.
26

Table of Contents
Reconciliation to the most directly comparable U.S. GAAP measure of all non-GAAP measures included in this Report is as follows (in thousands):

|  | Three Months Ended March 31, |
|  | 2025 |  |  | 2024 |
Net loss |  | $ | (2,432 | ) |  | $ | (3,368 | )
Adjustments: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 1,220 |  |  |  | 1,249 |
Amortization of operating lease right-of-use assets |  |  | 85 |  |  |  | 95 |
Loss on disposal of property and equipment |  |  | 34 |  |  |  | 13 |
Interest expense, net |  |  | 417 |  |  |  | 479 |
Non-GAAP EBITDA |  |  | (676 | ) |  |  | (1,532 | )
Stock-based compensation expense |  |  | 129 |  |  |  | 112 |
Inventory write-off |  |  | — |  |  |  | 141 |
Non-GAAP adjusted EBITDA |  | $ | (547 | ) |  | $ | (1,279 | )

Liquidity and Capital Resources
As of March 31, 2025, we had working capital of $0.7 million compared to working capital of $2.0 million as of December 31, 2024. The change in working capital was primarily the result of a decreases in cash and cash equivalents, offset by increases in inventories and accounts payable. Cash and cash equivalents and restricted cash were $7.8 million as of March 31, 2025, as compared to $8.6 million as of December 31, 2024.
In September 2021, we entered into the Senior Term Facility with MidCap, also acting as the administrative agent, and the lenders identified therein and borrowed $8.0 million in the form of a senior term loan. The term loan bore interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year. In September 2022, we amended the credit facility to transition, upon the cessation of LIBOR, to bear interest at one-month Secured Overnight Financing Rate (“SOFR”), or such other applicable period, plus 0.10%, with a floor of 0.50%. In June 2023, we amended the credit facility to: (i) refinance our existing $8.0 million term loan, (ii) borrow an additional $7.0 million, and (iii) provide for an additional $5.0 million tranche that could have been drawn under certain conditions in 2024. The facility matures on June 1, 2028. Borrowings under the credit facility bear interest at a rate per annum equal to the sum of (a) the greater of (i) the sum of (A) 30-day forward-looking term rate of one month SOFR, as published by CME Group Benchmark Administration Limited, from time to time, plus (B) 0.10%, and (ii) the applicable floor rate of 3.50%, with such sum reset monthly, and (b) 7.50%. We are obligated to make interest-only payments through June 2026. From July 2026 to maturity, we will make principal payments in 24 equal installments. We also amended and restated the existing warrant to allow MidCap to purchase 80,000 shares of our common stock at an exercise price of $8.80 per share for a 10-year period ending June 30, 2033. The loan is senior to all other indebtedness and is secured by substantially all of our assets. We are subject to customary affirmative and negative covenants, including a financial covenant based on minimum net revenue thresholds. Upon an event of default, including a covenant violation, all principal and interest are due on demand.
In February 2024, the parties amended the credit facility to, among other things, revise the applicable minimum net revenue threshold financial covenant. For the trailing 12-month period ended March 31, 2025, this amount was set at $30.5 million, increasing to $33.0 million as set forth in such amendment for the trailing 12-month periods thereafter. In March 2024, the credit facility was further amended (as amended to date, “Senior Term Facility”) to clarify certain provisions related to the maintenance of cash collateral accounts.
27

Table of Contents
In January 2022, we acquired certain assets related to the TheraClear devices from Theravant Corporation (“Theravant”). Theravant is eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones ($1.0 million of which is due upon the earlier of achieving a revenue target or July 2025), up to $20.0 million in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $0.5 million in future milestone payments upon the achievement of certain development and commercialization related targets. Through March 31, 2025, we have incurred an aggregate of $0.2 million of royalty and gross profit payments based on gross profit from domestic and international sales.
In October 2021, we entered into an equity distribution agreement with an investment bank under which we may sell up to $11.0 million of our shares of common stock in registered “at-the-market” offerings. The shares will be offered at prevailing market prices, and we will pay commissions of up to 3.00% of the gross proceeds from the sale of shares sold through our agent, which may act as an agent and/or principal. We have no obligation to sell any shares under this agreement and may, at any time, suspend solicitations under this agreement. In July 2024, we sold 665,136 shares of our common stock for gross proceeds of approximately $2.1 million. As of March 31, 2025, we may sell up to an additional $8.9 million shares of our common stock under this distribution agreement.
We cannot predict our revenues and expenses in the short term as a result of potential future pandemics, the ongoing Russia-Ukraine war, the Middle East conflict, changes in U.S. trade policies, supply chain disruptions, rising interest rates and related responses by our customers and our ultimate consumers as a result thereof. Based on our current business plan, we believe that our cash and cash equivalents, combined with the anticipated revenues from the sale or use of our products and operating expense management, will be sufficient to satisfy our working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with our existing operations for at least the next 12 months following the date of the issuance of these interim condensed consolidated financial statements. However, if these sources are insufficient to satisfy our liquidity requirements, we may seek to sell additional debt or equity securities or enter into a new credit facility or another form of third-party funding or seek other debt financing. If we raise additional funds by issuing equity or equity-linked securities, our stockholders would experience dilution and any new equity securities could have rights, preferences, and privileges superior to those of holders of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all. It is also possible that we may allocate significant amounts of capital towards products or technologies for which market demand is lower than expected and, as a result, abandon such efforts. If we are unable to maintain our current financing or obtain adequate additional financing when we require it, or if we obtain financing on terms which are not favorable to us, or if we expend capital on products or technologies that are unsuccessful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, or we may be required to delay the development, commercialization and marketing of our products.
Net cash used in operating activities was $0.6 million for the three months ended March 31, 2025, compared to net cash used in operating activities of $0.8 million for the three months ended March 31, 2024. The decrease in cash used in operating activities is primarily the result of a decrease in the net loss of approximately $0.9 million, partially offset by an increase in cash used by changes in current balance sheet accounts in the ordinary course of business of approximately $0.6 million, primarily due to a decrease of $0.6 million from accounts receivable due to increased sales to international customers who take longer to pay.
Net cash used in investing activities was $0.2 million for the three months ended March 31, 2025, compared to net cash used in investing activities of $0.7 million for the three months ended March 31, 2024. The decrease is primarily the result of a greater emphasis on refurbishing units that have been recalled from underperforming accounts as part of our stated plan to realign devices, which has a lower cost than building new units.
There was no net cash from financing activities for the three months ended March 31, 2025, compared to net cash used by financing activities of $18.0 thousand for the three months ended March 31, 2024. The financing activity for the three months ended March 31, 2024 was due to our payment of contingent consideration to Theravant.
28

Table of Contents
Commitments and Contingencies
A description of our commitments and contingencies is discussed in Note 12, Commitments and Contingencies to the Notes to unaudited condensed consolidated financial statements.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 1, Basis of presentation to the Notes to unaudited condensed consolidated financial statements.
Off-Balance Sheet Arrangements
The Company did not have any off-balance sheet arrangements as of March 31, 2025.

ITEM 3. | Quantitative and Qualitative Disclosure about Market Risk

Not applicable.

ITEM 4. | Controls and Procedures

Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), as of March 31, 2025. Based on that evaluation, management has concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level because of a material weakness in our internal control over financial reporting that had not yet been remediated at March 31, 2025. As of December 31, 2024, management identified a material weakness in our internal controls over financial reporting related to a lack of detailed management review of account reconciliations and account analyses, including those prepared by third-party specialists. In order to remediate this material weakness, we are improving our processes and controls, including senior management review, to achieve accurate financial accounting, reporting and disclosures.
Limitations of Internal Control System
Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud.
Changes in Internal Control over Financial Reporting
Other than in connection with executing on the continued implementation of the remediation measures referenced above, there have been no changes in our internal control over financial reporting in our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
29

Table of Contents
PART II - Other Information

ITEM 1. | Legal Proceedings

From time to time in the ordinary course of our business, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material, in which case, we will make separate disclosure as required. For the three months ended March 31, 2025, there have been no reportable legal proceedings or material developments to previously reported legal proceedings.

ITEM 1A. | Risk Factors

In addition to the risk factor described below, a description of the risks associated with our business, financial conditions and results of operations is set forth in Item 1A of our 2024 Form 10-K for the fiscal year ended December 31, 2024 and filed with the SEC on March 28, 2025.
Changes in the United States trade policy, including the impact of recently announced baseline tariffs, may have a material adverse effect on our business and results of operations.
In recent months, the U.S. government has signaled changes to its trade policy, including an intent to proceed with the imposition of tariffs on countries with which the U.S. trades, which could lead to corresponding punitive actions and retaliatory tariffs by such countries. For example, on April 2, 2025, the U.S. government announced a baseline tariff of 10% on products from all countries and an additional country-specific tariff on an incremental number of other countries. On April 9, 2025, the U.S. government announced a 90-day delay in the enforcement of the previously announced country-specific tariffs, however the 10% baseline tariff remains in place for all countries.
These tariff and fee announcements have been followed by announcements of specific exemptions and temporary pauses, as well as retaliatory tariffs and trade restrictions, resulting in additional uncertainty in our business. These actions may further boost U.S. inflation, resulting in an increase in the cost of manufacturing our products, reduced customer purchasing power, declining consumer confidence, increased price pressure, and reduced or cancelled orders and increased supply chain costs.

ITEM 5. | Other Information

During the quarter ended March 31, 2025, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (each as defined in Item 408(a) and (c) of Regulation S-K).
30

Table of Contents

ITEM 6. | EXHIBITS

16.1 | Letter from Marcum LLP to the Securities and Exchange Commission dated April 25, 2025 (incorporated by reference to Exhibit 16.1 in our Form 8-K filed on April 25, 2025).
31.1 | Rule 13a-14(a) Certificate of Chief Executive Officer
31.2 | Rule 13a-14(a) Certificate of Chief Accounting Officer
32.1* | Certifications of Chief Executive Officer and Chief Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
31

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

|  | STRATA SKIN SCIENCES, INC.
Date | May 14, 2025 | By: | /s/ Dolev Rafaeli
|  |  | Name: | Dolev Rafaeli
|  |  | Title: | President & Chief Executive Officer
|  |  |  | (Principal Executive Officer)
Date | May 14, 2025 | By: | /s/ John Gillings
|  |  | Name: | John Gillings
|  |  | Title: | Chief Accounting Officer
|  |  |  | (Principal Financial Officer)

32